1-[(5-Phenylthiophen-2-yl)methyl]piperazine | 1000933-43-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-[(5-Phenylthiophen-2-yl)methyl]piperazine
• CAS: 1000933-43-6
• 化学式: C₁₅H₁₈N₂S
• mdl: MFCD09971507
• 分子量: 258.387
• InChiKey: ICTGLJZWSFWSGS-UHFFFAOYSA-N

物化性质

• 沸点：
  385.6±37.0 °C(Predicted)
• 密度：
  1.140±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  43.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-[(5-Phenylthiophen-2-yl)methyl]piperazine 、 对硝基苯基氯甲酸酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以250 mg的产率得到4-nitrophenyl 4-((5-phenylthiophen-2-yl)methyl)piperazine-1-carboxylate
  参考文献：
  名称：

  Characterization of Tunable Piperidine and Piperazine Carbamates as Inhibitors of Endocannabinoid Hydrolases

  摘要：

  Monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH) are two enzymes froth the serine hydrolase superfamily that degrade the endocannabinoids 2-arachidonoylglycerol and anandamide, respectively. We have recently discovered that MAGL and FAAH arc both inhibited by carbamates bearing an N-piperidine/piperazine group. Piperidine/piperazine carbamates show excellent in vivo activity, raising brain endocannabinoid levels and producing CBI-dependent behavioral effects in mice, suggesting that they represent a promising class of inhibitors for studying the endogenous functions of MAGL and FAAH. Herein, we disclose a full account of the syntheses, structure-activity relationships, and inhibitory activities of piperidine/piperazine carbamates against members of the serine hydrolase family. These scaffolds can be tuned for MAGL-selective or dual MAGL-FAAH inhibition by the attachment of an appropriately substituted bisarylcarbinol or aryloxybenzyl moiety, respectively, on the piperidine/piperazine ring. Modifications to the piperidine/piperazine ring ablated inhibitory activity, suggesting a strict requirement for a six-membered ring to maintain potency.

  DOI：

  10.1021/jm9016976
• 作为产物：
  描述：

  在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 1-[(5-Phenylthiophen-2-yl)methyl]piperazine
  参考文献：
  名称：

  Characterization of Tunable Piperidine and Piperazine Carbamates as Inhibitors of Endocannabinoid Hydrolases

  摘要：

  Monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH) are two enzymes froth the serine hydrolase superfamily that degrade the endocannabinoids 2-arachidonoylglycerol and anandamide, respectively. We have recently discovered that MAGL and FAAH arc both inhibited by carbamates bearing an N-piperidine/piperazine group. Piperidine/piperazine carbamates show excellent in vivo activity, raising brain endocannabinoid levels and producing CBI-dependent behavioral effects in mice, suggesting that they represent a promising class of inhibitors for studying the endogenous functions of MAGL and FAAH. Herein, we disclose a full account of the syntheses, structure-activity relationships, and inhibitory activities of piperidine/piperazine carbamates against members of the serine hydrolase family. These scaffolds can be tuned for MAGL-selective or dual MAGL-FAAH inhibition by the attachment of an appropriately substituted bisarylcarbinol or aryloxybenzyl moiety, respectively, on the piperidine/piperazine ring. Modifications to the piperidine/piperazine ring ablated inhibitory activity, suggesting a strict requirement for a six-membered ring to maintain potency.

  DOI：

  10.1021/jm9016976

文献信息

• UREA COMPOUND OR SALT THEREOF
  申请人：Ishii Takahiro

  公开号：US20110172230A1

  公开（公告）日：2011-07-14

  [Object] To provide a compound which can be used for the treatment of a disease associated with fatty acid amide hydrolase (FAAH), particularly urinary frequency, urinary incontinence and/or overactive bladder. [Means for solution] It is confirmed that a urea compound chemical-structurally characterized by having a piperidine or piperazine ring or a salt thereof has an excellent FAAH-inhibitory activity, and thus the present invention is completed. The urea compound or its pharmaceutically acceptable salt of the present invention can increase the effective bladder capacity and ameliorate the state of urinary frequency, and is therefore useful as an agent for treating urinary frequency, urinary incontinence and/or overactive bladder.

  [目的] 提供一种化合物，可用于治疗与脂肪酸酰胺水解酶（FAAH）相关的疾病，特别是尿频、尿失禁和/或膀胱过度活动。 [解决方案] 确认具有哌啶或哌嗪环或其盐的尿素化合物在化学结构上具有出色的FAAH抑制活性，因此完成了本发明。本发明的尿素化合物或其药学上可接受的盐可以增加有效膀胱容量，改善尿频状态，因此可用作治疗尿频、尿失禁和/或膀胱过度活动的药物。